Clinical Study
A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting
Table 1
Clinical characteristics.
| | 0.3 mg | 0.45 mg | 0.6 mg | value | ( = 17) | ( = 15) | ( = 18) |
| Male | 8 (53.3%) | 12 (80.0%) | 13 (72.2%) | 0.157 | Age (year) | 58.94 ± 9.74 | 61.64 ± 7.76 | 57.72 ± 10.13 | 0.547 | Weight (kg) | 63.82 ± 11.83 | 62.94 ± 10.34 | 61.82 ± 9.07 | 0.385 | Height (cm) | 162.72 ± 4.92 | 164.31 ± 7.67 | 163.62 ± 7.55 | 0.885 | BSA (m2) | 1.69 ± 0.18 | 1.70 ± 0.16 | 1.67 ± 0.18 | 0.923 | Colon cancer | | | | | Stage III | 12 (71%) | 12 (80%) | 14 (78%) | 0.895 | Stage IV | 5 (29%) | 3 (20%) | 4 (22%) | | Use of rescue antiemetic | 3 (17.6%) | 5 (33.3%) | 3 (16.7%) | 0.810 |
|
|
Data are presented as mean ± standard deviation. BSA, body surface area
|